Bayer
NEWS
The results of the Phase III VICTORIA trial set up the potential for the companies to seek regulatory approval for vericiguat.
The research pact will leverage Dewpoint’s biomolecular condensates technology platform and Bayer’s small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
Bayer Plc launches LifeHub UK as part of a global network of Bayer global innovation hubs. LifeHub UK is designed to accelerate and optimise disease detection and data-driven drug discovery by developing Artificial Intelligence (AI)-enabled imaging solutions.
Expands on existing collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using clinical AI
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
In 2017, a lawsuit was filed alleging that Eli Lilly and Bayer, as well as other companies, attempted to use the free nursing services as a way to boost sales of diabetes drugs, such as Humalog and Humulin, as well as other drugs.
Companies from across the globe share updates on their business and pipelines.
JOBS
IN THE PRESS